Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 12 of 12 publications.

Winfree KB, Zhang KH, Muehlenbein CE, Panjic EH, Ale-Ali A, Graham CN. Budget impact of pirtobrutinib for patients with Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the United States (US). Poster presented at the ISPOR 2024; May 8, 2024. Atlanta, GA. [abstract] Value Health. 2024 Jun; 27(6 Supplement):S143. doi: 10.1016/j.jval.2024.03.2236

Zhang K, Shah C, Graham C, McBayne T, Schultz B. A cost model comparing long-term prophylaxis options for hereditary angioedema: lanadelumab and berotralsta. Poster presented at the AMCP Nexus 2023; October 17, 2023. Orlando, FL. [abstract] J Manag Care Spec Pharm. 2023 Oct; 29(10-a Suppl):S39. doi: 10.18553/jmcp.2023.29.10-a.s1

Zhang KH, Winfree K, Taipale KL, Muehlenbein CE, Panjic EH, Graham C. Estimation of the population of patients eligible for pirtobrutinib after Covalent Bruton Tyrosine Kinase Inhibitor (CBTKI) discontinuation in the United States. Poster presented at the ISPOR 2023 Conference; May 9, 2023. Boston, MA. [abstract] Value Health. 2023 Jun; 26(6 supplement):S187. doi: 10.1016/j.jval.2023.03.1013

Hamadani M, Graham C, Liao L, Zhang K, Strat HM, Ungar D, Ai W, Chen L, Carlo-Stella C. Long-term survival projections of loncastuximab tesirine-treated patients in relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL). J Clin Oncol. 2022 Jun;40(16_suppl):e19551.

Talon B, Perez A, Yan C, Alobaidi A, Zhang KH, Schultz BG, Suda KJ, Touchette DR. Economic evaluations of clinical pharmacy services in the United States: 2011-2017. J Am Coll Clin Pharm. 2020 Jun;3(4):793-806. doi: 10.1002/jac5.1199

Zhang K, Huang SP, Touchette D, Marko-Holguin M, Van Voorhees B. Cost-effectiveness of web-based depression programs for adolescents. Poster presented at the 2019 ISPOR 24th Annual International Meeting; May 2019. New Orleans, LA. [abstract] Value Health. 2019 May; 22(Suppl 2):S227. doi: 10.1016/j.jval.2019.04.1055

Ensor CR, Iasella CJ, Harrigan (Zhang) KM, Morrell MR, Moore CA, Shigemura N, Zeevi A, McDyer JF, Venkataramanan R. Increasing tacrolimus time-in-therapeutic range is associated with superior one-year outcomes in lung transplant recipients. Am J Transplant. 2018 Jun;18(6):1527-33. doi: 10.1111/ajt.14723

Harrigan (Zhang) K, Walton SM, Huang SP, Kumar VM, Chapman RH, Atlas SJ, Agboola FO, Ollendorf DA, Touchette DR. Long-term cost effectiveness of valbenazine and deutetrabenazine for tardive dyskinesia. Poster presented at the 2018 ISPOR 23rd Annual International Meeting; May 2018. Baltimore, MD. [abstract] Value Health. 2018 May; 21(Suppl 1):S184. doi: 10.1016/j.jval.2018.04.1257

Walton SM, Harrigan (Zhang) K, Touchette DR. Vesicular monoamine transporter 2 (VMAT2) inhibitors for tardive dyskinesia: effectiveness and value. 2017.

Thorpe CT, Fowler NR, Harrigan (Zhang) K, Zhao X, Kang Y, Hanlon JT, Gellad WF, Schleiden LJ, Thorpe JM. Racial and ethnic differences in initiation and discontinuation of antidementia drugs by Medicare beneficiaries. J Am Geriatr Soc. 2016 Sep;64(9):1806-14. doi: 10.1111/jgs.14403

Ensor CR, Harrigan (Zhang) K, Venkataramanan R, Morrell MR, Moore CA, Hayanga JA, Crespo MM, D’Cunha J, Zeevi A, McDyer JF. Increasing tacrolimus time-in-therapeutic range is associated with less cellular rejection in lung transplant recipients. Presented at the 2016 American Transplant Congress; June 12, 2016. Boston, MA.

Harrigan (Zhang) K, Thorpe JM. Racial and ethnic disparities in analgesic prescribing for migraine in U.S. emergency departments. Poster presented at the 142nd American Public Health Association (APHA) Annual Meeting; November 18, 2014. New Orleans, LA.